Recent Updates
Recently added Catalysts
MTVA Positive Sentiment Score: 75/100

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Monday, December 29, 2025 1 min read
Key Takeaway: MetaVia Inc. will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference from January 8-10 in Park City, Utah. The company's teams will engage with industry peers while promoting their innovative treatments for cardiometabolic diseases. MetaVia is developing DA-1726 and vanoglipel, both showing promising results in clinical trials.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant industry conference.
  • Showcases commitment to advancing cardiometabolic disease treatments.
  • Potential for networking and collaboration opportunities.

Full Press Release Details

CAMBRIDGE, Mass.,Dec. 29, 2025/PRNewswire/ --MetaVia Inc.(Nasdaq:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10thAnnual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah.

About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptidesGLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visitwww.metaviatx.com.

Contacts:

MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033[email protected]

Rx Communications GroupMichael Miller+1-917-633-6086[email protected]

SOURCE MetaVia Inc.

Frequently Asked Questions

What is the MASH-TAG 2026 Conference?

The MASH-TAG 2026 Conference is an annual event focused on advancements in cardiometabolic diseases.

When will the MASH-TAG 2026 Conference take place?

The conference is scheduled for January 8-10, 2026.

What treatments is MetaVia developing?

MetaVia is developing DA-1726 for obesity and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis.

What is DA-1726?

DA-1726 is a novel oxyntomodulin analogue aimed at promoting weight loss and glucose control.

What is vanoglipel's function?

Vanoglipel is a GPR119 agonist that enhances the release of gut peptides and improves glucose metabolism.

Tags: MTVA Viatris Investor Conferences Healthcare MetaVia MASH-TAG 2026 DA-1726 vanoglipel cardiometabolic diseases
Last updated: Dec 29, 2025